(PR-inside.com)
The final results of the open phase of the Prostate HistoScanning(TM) European multi-centre clinical study are published. The authors conclude that: "...Prostate HistoScanning(TM) has the potential to benefit the prostate cancer detection and staging pathway with increased cancer detection and tumour localisation...". WATERLOO (B), 13/12/2011 - Advanced Medical Diagnostics SA/NV (AMD), a privately held company that has developed HistoScanning(TM), today announced the publication of the final results from the open phase of the prospective, multi- centre and pan-European clinical study (PHS-02[i]), evaluating the Prostate HistoScanning(TM) application. HistoScanning(TM) is the award winning Tissue Characterisation modality that utilises raw ultrasound data. HistoScanning(TM) provides additional and meaningful information for better management of cancer patients by ..

More...